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Augmenting solute clearance in peritoneal dialysis.
Background. The removal of low molecular weight solutes by
peritoneal dialysis is less than by hemodialysis. The targets for
Kt/Vurea and creatinine clearance formulated in the Dialysis
Outcome Quality Initiative are unlikely to be achieved in a
substantial portion of peritoneal dialysis patients. Possibilities to
increase small solute clearances have therefore been subject to
many investigations.
Methods. A review of the literature and of recent new data on
determinants of solute removal, such as residual renal function,
the role of drained dialysate volume and manipulation of the
diffusive capacity of the peritoneum are presented.
Results. The contribution of residual GFR is more important
for the clearance of creatinine than for Kt/Vurea. It is even more
important for the removal of organic acids that are removed from
the body by tubular secretion. High dosages of furosemide
increase the urinary volume and the fractional Na1 excretion, but
have no effect on the magnitude of residual GFR, renal creatinine
clearance, renal urea clearance, and peritoneal transport charac-
teristics. The drained dialysate volume per day is the main
determinant of the peritoneal removal of urea. Its effect decreases
the higher the molecular weight of a solute. It can be augmented
by using large instillation volumes, by the application of more
exchanges, and by increasing peritoneal ultrafiltration. A large
exchange volume is especially effective in patients with an average
transport state, but in those with high solute transport rates,
Kt/Vurea is especially influenced by the number of exchanges.
Possibilities to increase ultrafiltration are discussed. The diffusive
capacity of the peritoneum can be augmented by using low
dosages of intraperitoneally administered nitroprusside. This in-
creases solute transport most markedly when it is applied in
combination with icodextrin as osmotic agent.
Conclusions. Small solutes clearances cannot be increased by
furosemide. Increasing the instilled volume of dialysis fluid and
the number of exchanges both affect solute clearance. Studies are
necessary on long-term effects of manipulation of the peritoneal
membrane with nitroprusside.
The objective of peritoneal dialysis is to remove uremic
toxins and excess fluid from the body; however, this goal is
not achieved by intermittent peritoneal dialysis (IPD) in
the majority of patients. Continuous ambulatory peritoneal
dialysis (CAPD) compensates for the low efficiency of the
peritoneal membrane by its continuous nature. Neverthe-
less, in the last few years concern has been expressed on the
adequacy of peritoneal dialysis with regard to solute re-
moval. This was especially based on the results of the
CANUSA study, showing a relationship between mortality
and parameters of solute transport such as Kt/Vurea and
creatinine clearance [1]. In the USA this has even led to
very strict adequacy targets for CAPD, such as Kt/Vurea $
2/week and creatinine clearance $ 60 liters/week/1.73 m2,
as expressed in the Dialysis Outcome Quality Initiative
(DOQI) [2]. Others have focused more on the importance
of control of hydration state and blood pressure for the
prognosis of peritoneal dialysis patients [3]. As peritoneal
clearances are dependent on the diffusive capacity of the
peritoneal membrane, expressed either as the dialysate/
plasma ratio (D/P) [4] or mass transfer area coefficient
(MTAC) [5], and the drained volume, measures to increase
clearances will lead to increased removal of waste products
and sometimes also to more ultrafiltration. This review
focuses on the role of residual renal function, the drained
volume and manipulation of the diffusive capacity of the
peritoneum in augmenting the clearances of low molecular
weight solutes.
RESIDUAL RENAL FUNCTION
Residual renal function may contribute importantly in
the removal of solutes during peritoneal dialysis. In 118
new peritoneal dialysis patients with a mean residual GFR
of 3.1 ml/min, removal by the native kidneys contributed
29% to the total Kt/Vurea and up to 48% of the total
creatinine clearance [6]. The endogenous creatinine clear-
ance is an inaccurate determinant of GFR in non-dialyzed
patients with renal failure, because tubular secretion of
creatinine may contribute considerably to the urinary ex-
cretion of this solute [7]. The mean of urea and creatinine
clearance provides a reasonable estimation of inulin clear-
ance for values below 15 ml/min in patients with chronic
renal failure [8]. This approach has also been used in
hemodialysis patients, where it appeared to underestimate
inulin clearance by 0.5 ml/min in a GFR of 3 ml/min [9].
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For CAPD patients the mean of urea and creatinine
clearance overestimated the GFR on average by 0.2 ml/min
[10], as shown in Figure 1.
Residual renal function is not only comprised of GFR.
Besides endocrine functions, tubular secretion is also im-
portant, especially for organic acids such as paraaminohip-
puric acid (Table 1). In CAPD patients who have on
average an equal contribution of renal and peritoneal
clearance in the removal of creatinine, the renal contribu-
tion in the removal of paraaminohippuric acid exceeded the
peritoneal contribution 4 to 5 times [11]. Little is known
about the toxicity of chronic exposure to these organic acids
in vivo, but it is evident that the DOQI statement on the
equivalency of residual renal and peritoneal clearances of
Fig. 1. Correlation between the clearance of
creatinine (CCr) and inulin (Ci) (A; r 5 0.96,
P < 0.01) and between the mean of urea and
creatinine clearance and inulin clearance (B;
r 5 0.98, P < 0.01), and the Bland and Altman
analysis of these parameters (C and D). The
dashed lines in the Bland and Altman analysis
indicate the 95% confidence interval. Note that
creatinine clearance overestimates GFR and
has a larger confidence interval (C) than the
mean of urea and creatinine clearance (D).
(Reprinted from the Journal of the American
Society of Nephrology [10] with permission from
Williams and Wilkins Company, Baltimore,
MD, USA.)
Table 1. Twenty-four hour renal and peritoneal clearances of inulin,










Median values are given. Based on [11].
Table 2. Acute effects of furosemide, 2 3 1000 mg orally in 7 stable
CAPD patients
No furosemide Furosemide
Urine production ml/min 0.27 0.66a
Inulin clearance ml/min 2.4 2.0
Creatinine clearance ml/min 5.4 3.7
Urea clearance ml/min 1.5 1.5
Fractional Na1 excretion % 7.9 26.7a
Median values are given. Data are from [16]; used with permission.
a P , 0.02
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small solutes is a simplification. Every ml/min loss of
residual GFR is accompanied by a loss of tubular secretion
of various solutes that can sometimes not be replaced by
peritoneal clearance, especially when a significant amount
of protein binding is present.
From the above considerations it follows that preserva-
tion or even an induced increase in residual renal function
is important for overall solute removal. Many studies have
shown that residual GFR is better preserved in peritoneal
dialysis patients than in hemodialysis patients [12–14].
Chronic administration of high dosages of furosemide is
used by some centers to increase urine volume in CAPD
patients. There is some evidence that this policy may retard
the progression to anuria [15]. We studied the acute effects
of furosemide in seven stable CAPD patients [16]. They
had a urine production ranging from 140 to 1900 ml/24 hr,
median 350 ml/24 hr. Any diuretics had been discontinued
two weeks before the study. The patients underwent a
standard peritoneal permeability analysis (SPA) as de-
scribed previously [5]. This was directly followed by a
24-hour urine collection and blood sampling for the calcu-
lation of renal clearances. Inulin (2.5 g) was administered
intravenously just before the SPA. Immediately after the
SPA the bladder was emptied by spontaneous voiding. This
was the starting point of the 24-hour collection period. The
procedure was repeated one week later, but it was preceded
by the oral administration of furosemide 1000 mg twice
daily, starting 24 hours before the second study period.
Furosemide had no effect on peritoneal solute and fluid
transport kinetics as measured with the SPA. The results
with regard to renal clearances are summarized in Table 2.
The urine production increased 2.5-fold, but no effect was
observed on the GFR and the clearances of urea and
creatinine. However, the fractional excretion of sodium
increased about three times, leading to a median increase
of sodium excretion of 54 mmol/24 hr. It follows from these
Fig. 2. Transcapillary ultrafiltration (f), effective lymphatic absorption (v) and the resulting change in intraperitoneal volume () in 8 stable CAPD
patients who were on a 2 liter exchange of 1.36% glucose (A) or with a 3 liter exchange of 1.36% glucose based dialysate (B). (Based on data from [19].)
Table 3. Effects of drained volume and of diffusive membrane
characteristics on peritoneal clearances of low- and middle-molecular















b2-microglobulin 11,800 2 11
Table 4. Effect of increasing the dialysis volume from 2 to 3 liters
(1.36% glucose) on the peritoneal mass transfer of low molecular
weight solutes, serum proteins and net ultrafiltration after
a 4 hour dwell
Solute 2 Liters 3 Liters % Change
Urea mmol/4 hr 61 6 19 85 6 31 39b
Creatinine mmol/4 hr 1849 6 319 2634 6 542 42c
Glucose mmol/4 hr 100 6 19 138 6 24 38b
b2-microglobulin mg/4 hr 9.0 6 2.2 9.5 6 2.9 6
Albumin mg/4 hr 881 6 225 938 6 200 6
IgG mg/4 hr 137 6 38 148 6 43 8
Net ultrafiltration ml/4 hr 107 6 54 2210 6 293 2296a
Data are means 6 SD of 8 patients. Based on [19].
a P , 0.05; b P , 0.01; c P , 0.001
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data that high dosages of furosemide increase the total
removal of water and sodium from the body, but have no
effect on Kt/Vurea and total creatinine clearance.
One study reported that an early start of hemodialysis
might lead to better preservation of residual creatinine
clearance [17]. No data are available on whether this might
also occur in peritoneal dialysis. It is also not known
whether long-term treatment with angiotensin converting
enzyme (ACE) inhibitors could influence the progression
to anuria in peritoneal dialysis patients.
DRAINED VOLUME
The dialysate flow rate, that is, the drained volume per
unit of time, is the only determinant of the peritoneal
clearance of a low molecular weight solute when a concen-
tration equilibrium is present between plasma and dialy-
sate. For instance, this is the case for urea during long
dwells. It is different for high molecular weight solutes
where no important effect of saturation of the dialysate is
present, such as for serum proteins. For these macromol-
ecules no effect of the drained volume is present [18], and
the diffusive capacity of the peritoneum is the determinant
of the peritoneal clearance (Table 3). The drained volume
can be increased by the use of large volumes for instillation,
by the application of more exchanges, and by increasing
peritoneal ultrafiltration.
Increasing the dialysate volume from 2 to 3 liters of
1.36% glucose in eight stable CAPD patients had no effects
on MTACs during a four hour dwell, but increased the
mass transfer of low molecular weight solutes by an average
of 40% (Table 4) [19]. No effect was present on the mass
transfer of serum proteins. However, the effective lym-
phatic absorption rate measured with intraperitoneally
administered autologous hemoglobin increased, with 89%
probably caused by the higher intraperitoneal pressure [20,
21]. This resulted in lower net ultrafiltration after four
hours with three liters of 1.36% glucose dialysate compared
to two liters, as shown in Figure 2. A more recent study in
rats using various volumes of 3.86% glucose dialysate
confirmed the absence of an effect of fill volume on
MTACs of low molecular weights solutes, as well as the
augmenting effect on small solute clearances [22]. Also, the
effective lymphatic absorption rate measured as the disap-
pearance rate of 131I-albumin was greater in this animal
Fig. 3. Relationship between the dialyzed volume and peritoneal urea clearance (A) and the relationship between dialyzed volume and the clearances
of various other solutes (B). (Reprinted from Medicine [23] with permission of the author and of Williams and Wilkins Company, Baltimore, MD, USA.)
Fig. 4. Computer predictions using the PD Adequest® software program
for Kt/Vurea using different dialysis prescriptions. Simulations were made
for anuric patients with a body surface area of 1.84 m2. The hatched bars
represent the values for a D/P ratio creatinine of 0.65 in the peritoneal
equilibration test with the use of only 2.27% glucose dialysate. The
stippled bars represent the values for a D/P ratio creatinine of 0.89 and the
use of only 3.86% glucose dialysate.
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model. Intraperitoneally administered albumin disappears
from the peritoneal cavity by direct uptake into the subdi-
aphragmatic lymphatics and by transport across the me-
sothelial layer into peritoneal interstitial tissues. The latter
route was especially increased after the administration of
large dialysate volumes. In contrast to the study in humans,
net ultrafiltration increased with higher fill volumes due to
the better persistence of the osmotic gradient. The differ-
ence is explained most likely by the fact that the human
studies were done with 1.36% glucose and the animal
studies with 3.86% glucose. It can therefore be concluded
that increasing the dialysate volume: (1) has no effect on
the diffusive characteristics of the peritoneal membrane;
(2) leads to greater mass transfer of low molecular weight
solutes due to the higher drained volume; (3) leads to an
increase in effective lymphatic absorption; and (4) has
effects on transcapillary ultrafiltration that are dependent
on the glucose concentration of the used dialysis fluids.
Peritoneal mass transport of low molecular weight sol-
utes can be increased by using a larger number of dialysis
exchanges. This can easily be done by using automated
peritoneal dialysis (APD). However, as already shown by
Boen, the maximum peritoneal urea clearance is achieved
with volumes of 3 to 3.5 liters per hour (Fig. 3) [23]. This is
explained by the time lost for drainage and instillation of
fresh dialysis fluids. Awareness of this phenomenon has
led to the concept of tidal peritoneal dialysis where only
50% of the intraperitoneal volume is exchanged. How-
ever, this will lead to a decrease in the diffusive gradient
during the dwells. Whether increasing the instilled vol-
ume or increasing the number of exchanges is more
efficacious is dependent on the diffusive characteristics of
the peritoneal membrane. In patients with an average
transport state in the PET, increasing the volume augments
Kt/V more than increasing the number of exchanges. In
those with high solute transport rates, Kt/Vurea is especially
influenced by the number of exchanges. This is illustrated
in Figure 4, where predictions were made using the PD
Adequest® program [24]. It follows from these computer
simulations that tidal peritoneal dialysis offers no real
advantage with regard to small solute clearance.
The drained volume can also be augmented by increasing
ultrafiltration. Net ultrafiltration in peritoneal dialysis is the
difference between transcapillary ultrafiltration and effec-
tive lymphatic absorption. Transcapillary ultrafiltration can
be enhanced by avoiding a very high intraperitoneal pres-
sure and by increasing the osmotic pressure gradient, such
as by using more hypertonic dwells. The use of 3.86%
glucose instead of 1.36% glucose had no effect on MTACs
[18, 25], but increased the clearances of urea and creatinine
by an average of 25% (Fig. 5). However, evidence is
accumulating that chronic exposure to these very high
glucose concentrations is an important pathogenetic factor
in the alterations that can develop in the peritoneal mem-
brane after long-term peritoneal dialysis [26]. Another way
to ensure high transcapillary ultrafiltration rates especially
during long dwells is the use of the glucose polymer
icodextrin [27].
Net ultrafiltration is also influenced by the effective
lymphatic absorption rate, measured as the disappearance
rate of intraperitoneally administered macromolecules.
Some drugs are likely to decrease this absorption rate,
leading to higher drained volumes. Examples are intraperi-
toneal phosphatidylcholine [28–30], oral bethanechol [31],
Fig. 5. Peritoneal clearances of urea,
creatinine and albumin during four hours
dwells with 1.36% glucose-based dialysate (A)
and with 3.86% glucose (B). Results are
expressed as box en whisker plots. The boxes
show the median values and the 25th and 75th
percentiles, and the extremes are represented
by the whiskers. (Based on data from [25].)
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and intraperitoneal hyaluronan [32]. Oral bethanechol
chloride is the only one that can currently be used in CAPD
patients, but its effectiveness has thus far not been con-
firmed in other studies.
PERITONEAL DIFFUSIVE CAPACITY
The diffusive capacity of a membrane is determined by
its surface area and its permeability or size-selectivity. It
has become evident that the transport of low molecular
weight solutes across the peritoneal membrane is mainly
dependent on its vascular surface area and hardly on its
permeability [33, 34]. Consequently, MTACs or D/P ratios
of low molecular weight solutes provide information on the
vascular peritoneal surface area, that is, the number of
perfused peritoneal capillaries or the number of pores
available for transport. In the past many attempts have
been made to increase the vascular surface area in animals
and in IPD patients by pharmacological methods, especially
by intraperitoneal administration of vasodilators. Intraperi-
toneal administration of the b-receptor agonist isoproter-
enol increased low molecular weight solute clearances in
rats [35], rabbits [36] and dogs [37], but hardly increased it
Fig. 6. Peritoneal clearances of urea,
creatinine and albumin using 1.36% glucose
based dialysate during a four hour dwell (A)
and in the same patients after intraperitoneal
administration of nitroprusside 4.5 mg/liter
(B). Peritoneal clearances of the same solutes
using 7.5% icodextrin based dialysate during an
eight hour dwell (C) and in the same patient
after intraperitoneal administration of
nitroprusside 4.5 mg/liter (D). (Based on data
from references [47, 48].)
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in IPD patients [38]. Intraperitoneal administration of the
a receptor blocker phentolamine had no effect on solute
clearances in IPD patients [38]. This lack of effect was also
found for the vasodilators hydralazine [38], and papaverine
[39], while the effect of diazoxide was only limited [38].
Oral dipyridamole increased peritoneal inulin clearance
and glucose absorption in IPD patients without a significant
effect on the clearances of urea and creatinine [40]. In a
subsequent study by the same authors in CAPD patients no
effects were found [41]. A small number of studies has been
published on effects of antihypertensives in CAPD patients.
In one study oral clonidine had no effect on peritoneal
creatinine clearance, but nifedipine and enalapril increased
it by an average of 13% [42]. However, in another study no
effect of either orally or intraperitoneally administered
enalapril was found on the peritoneal clearances of urea
and creatinine [43].
The effects of all these pharmacological interventions are
much less than those of intraperitoneally administered
nitroprusside. This direct nitric oxide donor induced
marked increases in the peritoneal clearances of low mo-
lecular weights solutes in animals [35, 44], and in IPD
patients [38, 45, 46]. The finding that peritoneal protein loss
also increased, suggested that nitroprusside not only en-
larged the vascular surface area, but also increased the
permeability of the peritoneal membrane. Recently we
studied the effects of intraperitoneal administration of
nitroprusside 4.5 mg/liter during single dwells in stable
CAPD patients [47, 48]. The drug was administered to
patients with either 1.36% glucose-based dialysate and
studied during four hour dwells [47], or to 7.5% icodextrin-
based dialysate and studied during eight-hour dwells [48].
No effect on blood pressure was found. Both studies were
done in 10 stable CAPD patients. Each patient was studied
during a SPA without the administration of nitroprusside,
and again on another day during a SPA with intraperitoneal
nitroprusside. The interval between the two SPAs was less
than one week. The effect on the clearances of urea,
creatinine and albumin is shown in Figure 6. The increase
in the clearance of urea during the 1.36% glucose SPA was
4% (NS), that of creatinine 16% (P , 0.01), and that of
albumin 75% (P , 0.01). During the 7.5% icodextrin SPAs
urea clearance increased 13%, creatinine clearance 15%,
and albumin clearance 47%, P , 0.01 for all solutes. It
could be estimated that when the glucose-based night
exchange would be replaced by a 7.5% icodextrin exchange
with nitroprusside, this would increase the peritoneal cre-
atinine clearance with on average 6 liters per week and
peritoneal albumin loss with 0.9 grams per day. However,
these are just extrapolations based on single standardized
exchanges. A clinical trial is necessary to prove whether
these predictions are correct during chronic administration,
and whether this can be done without damaging the
peritoneal membrane.
CONCLUSIONS
Increasing the urine output in peritoneal dialysis patients
with residual renal function by furosemide does not in-
crease small solute clearances. Increasing the instilled
volume of dialysis fluid and the number of exchanges both
affect solute clearance, but have their limitations. Manip-
ulation of the vascular peritoneal surface area, such as with
nitroprusside, may be an interesting possibility, but more
studies are needed on this subject.
Reprint requests to Raymond T. Krediet, M.D., Academic Medical Center,
Renal Unit, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.
APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; APD, automated peritoneal dialysis; DOQI, Dialysis Outcome
Quality Initiative; D/P ratio, dialysis/plasma ratio; GFR, glomerular
filtration rate; IPD, intermittent peritoneal dialysis; Kt/V, dialysis dose;
MTAC, mass transfer area coefficient; SPA, standard peritoneal perme-
ability analysis.
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